CEO, TRL Therapeutics, Inc.
Derrell D. Porter, MD is a physician-entrepreneur with years of experience in the business of medicine, and one of the few experts with dual capabilities in developing and commercializing rapidly evolving cell therapies. Dr. Porter is currently CEO of an emerging biotech called cTRL Therapeutics, a company that harnesses circulating tumor reactive lymphocytes to broaden the power and reach of solid tumor cell therapy. Prior to his current role, he founded a cell therapy biotech called Cellevolve Bio. Derrell has held roles of increasing responsibility at several leading biopharmaceutical companies: Atara Bio, Gilead, AbbVie, among others. He started his career at McKinsey & Company. Dr. Porter earned his MD from University of Pennsylvania’s Perelman School of Medicine, where he was a Gamble Scholar, and an MBA from The Wharton School. He earned his Bachelor of Science in Neuroscience from the University of California, Los Angeles (UCLA). Additionally, he is on the boards of Passage Bio (NASDAQ: PASG), a Philadelphia-based genetics medicine company and Acumen Pharma (NASDAQ: ABOS), an Alzheimer’s Disease focused on developing amyloid beta oligomers targeted therapies. Dr. Porter also serves as an Advisory Committee Member for the Penn School of Medicine.
Outside of the office, Derrell enjoys spending time with his wife and kids, non-fiction reading, Pac-12 (now BigTen) sports, traveling the world, and road cycling.